Table Graph
      published meta-analysis   sensitivity analysis   studies

favipiravir in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsShenoy S, 2021 1.32 [0.58; 2.99] 1.32[0.58; 2.99]Shenoy S, 202110%353NAnot evaluable clinical improvement (time to event analysis only)detailed resultsShenoy S, 2021 0.99 [0.77; 1.28] Shinkai, 2021 1.40 [0.91; 2.15] 1.13[0.81; 1.56]Shenoy S, 2021, Shinkai, 2021246%936seriousnot evaluable hospital dischargedetailed resultsShenoy S, 2021 1.06 [0.85; 1.32] 1.06[0.85; 1.32]Shenoy S, 202110%780NAnot evaluable hospitalizationdetailed resultsHolubar M, 2021 0.12 [0.01; 2.26] 0.12[0.01; 2.26]Holubar M, 202110%149NAnot evaluable viral clearance detailed resultsHolubar M, 2021 0.76 [0.48; 1.20] 0.76[0.48; 1.20]Holubar M, 202110%149NAnot evaluable viral clearance (time to event analysis only)detailed resultsHolubar M, 2021 0.76 [0.48; 1.20] 0.76[0.48; 1.20]Holubar M, 202110%149NAnot evaluable serious adverse eventsdetailed resultsShinkai, 2021 2.80 [0.14; 56.95] 2.80[0.14; 56.95]Shinkai, 202110%156NAnot evaluable adverse eventsdetailed resultsHolubar M, 2021 2.07 [0.89; 4.83] Shinkai, 2021 19.54 [7.77; 49.11] 6.31[0.70; 56.96]Holubar M, 2021, Shinkai, 2021292%302lownot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-05-04 09:43 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 513 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons